1. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non–Small Cell Lung Cancer: A Phase I Study 
Kristin A. Higgins, MD, Rathi N. Pillai, MD, Zhengjia Chen, PhD, Sibo Tian, MD, Chao Zhang, PhD, Pretesh Patel, MD, Suchita Pakkala, MD, Jay Shelton, MD, Seth D. Force, MD, Felix G. Fernandez, MD, Conor E. Steuer, MD, Taofeek K. Owonikoko, MD, PhD, Suresh S. Ramalingam, MD, Jeffrey D. Bradley, MD, Walter J. Curran, MD 
Journal of Thoracic Oncology 
Volume 12, Issue 11, Pages (November 2017)
DOI: /j.jtho
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
The treatment schema and different dose cohorts for this phase I study.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
The top panel shows isodose lines for a patient treated in dose cohort 1 overlaid on the image from the second planning computed tomography (CT) scan, performed after 40 Gy of chemoradiation was delivered. A dose of 9 Gy × 2 was delivered to the residual disease. The cumulative isodose lines are shown. The bottom left panel shows the patient’s pretreatment CT scan, and the bottom right panel shows the CT scan performed 12 weeks after treatment, which shows complete resolution of bulky aortopulmonary window adenopathy.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

4. Figure 3
Kaplan-Meier curves for local regional control (green), distant metastases–free survival (red), and overall survival (blue) for all patients enrolled in this study.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions